Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is a commercial-stage biopharmaceutical company with a strong pipeline of monoclonal antibody therapies targeting serious viral infectious diseases, including COVID-19, RSV, measles, and more. The company's lead product, PEMGARDA, has already received emergency use authorization from the FDA and has a strong market potential with a peak penetration of 60% in the US and 30% in the EU. The company's next-generation antibody candidates, including VYD2311 for COVID-19, also have promising data with over 56% of completed treatment days on 4/9. With a robust clinical program, differentiated product profile, and potential for significant revenue growth, Invivyd is positioned for success in the competitive biopharmaceutical market.

Bears say

Invivyd is currently heavily reliant on the success of its mAb for COVID-19, PEMGARDA, which has received emergency use authorization for certain immunocompromised individuals. However, the company's other mAb candidates for COVID-19, VYD2311 and VBY329, are not expected to reach clinical development until 2027, leaving a significant gap in potential revenue for the company. Additionally, the company faces risks from clinical development, competition, novel modality, and commercialization, which could hinder its ability to successfully bring its mAbs to market. These factors contribute to the overall negative outlook on Invivyd's stock.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.